title: Cardiovascular risk and dyslipidemia management in HIV-infected patients.
abstract: HIV infection and antiretroviral therapy each appear to increase cardiovascular disease risk. Increased risk may be attributable to the inflammatory effects of HIV infection and dyslipidemia associated with some antiretroviral agents. The prevalence of cardiovascular disease is increasing as patients live longer, age, and acquire traditional coronary heart disease (CHD) risk factors. In general, any additional cardiovascular risk posed by HIV infection or antiretroviral therapy is of potential concern for patients who are already at moderate or high risk for CHD. Long-term and well-designed studies are needed to more accurately ascertain to what degree HIV infection and antiretroviral therapy affect long-term cardiovascular disease risk. Management of dyslipidemia to reduce CHD risk in HIV-infected patients is much the same as in the general population, with the cornerstone consisting of statin therapy and lifestyle interventions. Smoking cessation is a major step in reducing CHD risk in those who smoke. This article summarizes a presentation by James H. Stein, MD, at the IAS-USA live continuing medical education activity held in New York City in March 2012.
authors.affiliation: Division of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.
authors.forename: James H
authors.initials: JH
authors.lastname: Stein
mesh_terms: D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003327:Coronary Disease / Q000453:epidemiology* / Q000517:prevention & control; D050171:Dyslipidemias / Q000139:chemically induced / Q000628:therapy*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D012307:Risk Factors
chemical_list: D044966:Anti-Retroviral Agents